Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

support provided by the HVTN."

Dr. McNally concluded, "We believe we are well-positioned for success in 2009 and beyond, with our preventative vaccine beginning Phase 2 human testing and our therapeutic vaccine trial in the planning stage. Based on highly promising results in preclinical non-human primate studies conducted by Dr. Rama Amara at Emory University, we are eager to launch a therapeutic Phase 1/2 human clinical trial in individuals already infected with HIV to investigate the use of our vaccine as a therapeutic treatment to control HIV-virus levels. We expect this trial may start in mid-2009 and we will report on the development of this program as we conclude plans with our trial sponsor."

GEOVAX LABS, INC.

Condensed Consolidated Statements of Operations Information

(amounts in thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues:

Grant Revenue $1,322 $- $2,298 $-

Operating expenses:

Research and

development 1,362 360 2,725 1,273

General and

administrative 699 815 2,322 1,865

2,061 1,175 5,047 3,138

Other income:

Interest income 17 9 60 52

17 9 60 52

Net loss $(722) $(1,166) $(2,689) $(3,086)

Loss per common share $(0.00) $(0.00) $(0.00) $(0.00)

GEOVAX LABS, INC.

Con
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 ... today the signage of a distribution agreement with ... is now distributing Myriant’s bio-succinic acid in the ... and Ireland, targeting customers in the industrial and ... distribution powerhouse, Azelis offers a far-reaching chemical portfolio ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... September 02, 2014 The inventors of ... for chronic tinnitus are seeking support for development costs ... Indiegogo platform ( http://igg.me/at/tinaway ), was launched on September ... therapeutic ‘mHealth’ app and is based on ten years ... team of biomedical and software engineers, Dr. Ian Dixon ...
(Date:8/31/2014)... 01, 2014 Available spectra is ... for research and cultivation of a wide range ... proprietary LEDs with proven patented and pending wide ... light uniformity in critical applications in contrast to ... , “Our customers have a large variety of ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... Pacira Pharmaceuticals, Inc., an,acute care specialty pharmaceutical company, today ... addition of a key senior,executive to the company,s management ... a seasoned biopharmaceutical executive with more than,30 years of ... Pacira as the founder and past Chairman and CEO ...
... WOODCLIFF LAKE, N.J., July 9 Par,Pharmaceutical Companies, Inc. ... shipment of 12.5mg and 25mg meclizine HCl tablets immediately. ... of the AB-rated,generic product., Par marketed meclizine prior ... in February 2008. Par has since qualified a new ...
... 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX:,LOR, ... biopharmaceutical company,specializing in the research and development ... of cancer, today announced progress made in,the ... two,research studies on the Virulizin(R) mode of ...
Cached Biology Technology:Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management 2Par Pharmaceutical to Launch meclizine HCL Tablets 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6
(Date:9/2/2014)... long, spiky legs and their propensity for eating anything, ... nightmares. And now research from North Carolina State University ... homes across the eastern United States. , "The good ... any kind of threat to humans," says Dr. Mary ... lead author of a paper about the research. , ...
(Date:9/2/2014)... are done in by it. New research at Rockefeller ... stress gap in mice with very similar genetic backgrounds ... understand the development of psychiatric disorders such as anxiety ... experiences as it goes through its life. And we ... of genes, and as a result, affect an animal,s ...
(Date:9/1/2014)... diet showed some modest improvement in the last decade ... consumption of unhealthy trans fats, but the gap in ... poor. , , An unhealthy diet is closely linked ... healthy diet is an important part of the strategy ... diet quality is important because it can offer guidance ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... York, N.Y. (November 8, 2012) Autism Speaks, the world,s ... the release of biological and clinical data from 383 new ... to researchers. AGRE is a resource for scientists that is ... two or more children on the autism spectrum. These 383 ...
... least 126,000 sites across the U.S. have contaminated groundwater that ... considered "complex," meaning restoration is unlikely to be achieved in ... says a new report from the National Research Council. ... at these sites ranges from $110 billion to $127 billion, ...
... emerging field tissue regeneration, which harnesses the power and healing ... the world are turning their attention to. One of the ... State University, today announced the opening of SDSU,s new Integrated ... research in San Diego. Speaking at the Frontiers ...
Cached Biology News:Autism Speaks announces the release of new genetic data for researchers 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 3